Osaic Holdings
RARE icon

Osaic Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Osaic Holdings’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.2K Sell
1,713
-1,163
-40% -$28.9K ﹤0.01% 5379
2026
Q1 		$60.3K Sell
2,876
-240
-8% -$5.4K ﹤0.01% 5064
2025
Q4 		$71.7K Sell
3,116
-2,879
-48% -$94.7K ﹤0.01% 4984
2025
Q3 		$180K Buy
5,995
+1,255
+26% +$37.6K ﹤0.01% 4306
2025
Q2 		$172K Buy
4,740
+4,634
+4,372% +$167K ﹤0.01% 4062
2025
Q1 		$3.84K Sell
106
-391
-79% -$16.3K ﹤0.01% 6310
2024
Q4 		$15.6K Buy
497
+170
+52% +$8.43K ﹤0.01% 5512
2024
Q3 		$18.2K Sell
327
-160
-33% -$8.15K ﹤0.01% 5442
2024
Q2 		$20K Sell
487
-317
-39% -$13.5K ﹤0.01% 5342
2024
Q1 		$37.5K Sell
804
-4,024
-83% -$190K ﹤0.01% 4941
2023
Q4 		$231K Sell
4,828
-2,591
-35% -$100K ﹤0.01% 3799
2023
Q3 		$264K Sell
7,419
-159
-2% -$6.3K ﹤0.01% 3785
2023
Q2 		$349K Buy
7,578
+1,982
+35% +$91.9K ﹤0.01% 3459
2023
Q1 		$224K Buy
5,596
+688
+14% +$29.5K ﹤0.01% 3778
2022
Q4 		$229K Buy
4,908
+1,018
+26% +$40K ﹤0.01% 3728
2022
Q3 		$162K Buy
3,890
+1,000
+35% +$51.4K ﹤0.01% 3945
2022
Q2 		$171K Buy
2,890
+75
+3% +$4.62K ﹤0.01% 3943
2022
Q1 		$198K Sell
2,815
-15
-0.5% -$1.04K ﹤0.01% 4039
2021
Q4 		$236K Buy
2,830
+1,218
+76% +$99.1K ﹤0.01% 3796
2021
Q3 		$146K Buy
1,612
+339
+27% +$30.6K ﹤0.01% 4204
2021
Q2 		$122K Sell
1,273
-1,401
-52% -$146K ﹤0.01% 4311
2021
Q1 		$306K Buy
2,674
+852
+47% +$116K ﹤0.01% 3360
2020
Q4 		$253K Buy
1,822
+248
+16% +$29.4K ﹤0.01% 3261
2020
Q3 		$128K Buy
1,574
+418
+36% +$34.6K ﹤0.01% 3616
2020
Q2 		$90K Buy
1,156
+197
+21% +$13K ﹤0.01% 3759
2020
Q1 		$43K Buy
+959
New +$49.8K ﹤0.01% 4081

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Osaic Holdings's RARE Position: Q2 2026 in Review

Osaic Holdings reduced its Ultragenyx Pharmaceutical (RARE) stake by 40% in Q2 2026, selling an estimated $28.9K and leaving 1,713 shares worth $57.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5379.

Osaic Holdings first reported a position in RARE in Q1 2020 and has held it in 26 quarters since. The position peaked at $349K in Q2 2023. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Osaic Holdings held 1,713 shares of Ultragenyx Pharmaceutical worth $57.2K as of Q2 2026.
  • Osaic Holdings sold 1,163 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $28.9K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #5379 holding.
  • Osaic Holdings first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Ultragenyx Pharmaceutical position peaked at $349K in Q2 2023.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.